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ABSTRACT 
Background 
Chronic fatigue syndrome is likely to be a heterogeneous condition. Previous 
studies have empirically defined subgroups using combinations of clinical and 
biological variables. We aimed to explore the heterogeneity of chronic fatigue 
syndrome. 
Methods 
We used baseline data from the PACE trial, which included 640 participants with 
chronic fatigue syndrome. Variable reduction, using a combination of clinical 
knowledge and principal component analyses, produced a final dataset of 26 
variables for 541 patients. Latent class analysis was then used to empirically 
define subgroups.  
Results 
The most statistically significant and clinically recognisable model comprised 
five subgroups. The largest, “core” subgroup (33% of participants), had 
relatively low scores across all domains and good self-efficacy. A further three 
subgroups were defined by: the presence of mood disorders (21%); the 
presence of features of other functional somatic syndromes (such as 
fibromyalgia or irritable bowel syndrome) (21%); or by many symptoms – a 
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group which combined features of both of the above (14%). The smallest 
“avoidant-inactive” subgroup was characterised by physical inactivity, belief 
that symptoms were entirely physical in nature, and fear that they indicated 
harm (11%). Differences in the severity of fatigue and disability provided some 
discriminative validation of the subgroups. 
Conclusions 
In addition to providing further evidence for the heterogeneity of chronic 
fatigue syndrome, the subgroups identified may aid future research into the 
important aetiological factors of specific subtypes of CFS and the development 
of more personalised treatment approaches.  
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Introduction 
Chronic fatigue syndrome (CFS) is a chronic disabling condition with an estimated population 
prevalence of 0.2-0.4% (National Institute for Health and Clinical Excellence 2007). Opinions differ as 
to whether myalgic encephalomyelitis (ME) and CFS are the same condition (Prins et al. 2006). In the 
absence of reliable biomarkers or clinical signs, diagnosis is based upon self-reported symptoms and 
the exclusion of alternative explanatory diagnoses. Several case definitions are commonly used for 
research (Sharpe et al. 1991; Fukuda et al. 1994; The National Task Force on Chronic Fatigue 
Syndrome 1994), although of the twenty published to date, all assessments of reproducibility and 
validation are limited by the absence of a gold standard. (Brurberg et al. 2014) 
The reliance upon self-reported symptoms has led to doubts about the validity of CFS as an 
aetiologically homogenous diagnosis (Wakefield 2013; Komaroff 2015). As such, the last 20 years has 
seen much research examining the potential heterogeneity of CFS, with multiple attempts to 
empirically define cases and subgroups.  
Initial work by Hickie et al used symptoms and demographics to empirically define a core group and 
a smaller polysymptomatic subgroup (Hickie et al. 1995; Wilson et al. 2001). Further studies have 
suggested empirical subgroups of CFS resembling fibromyalgia (Hadzi-Pavlovic et al. 2000), whilst 
others found that CFS and fibromyalgia could not be empirically distinguished (Sullivan et al. 2002). 
The inclusion of biological variables in studies suggests these may also be important in defining 
illness subgroups. These include body-mass index (BMI); sleep-disordered breathing and insomnia; 
sympathetic nervous system activity; and endocrine features of metabolic strain (Vollmer-Conna et 
al. 2006; Aslakson et al. 2009). When such biological variables were combined with the variables of 
many symptoms  and depression, they could empirically identify validated subgroups of CFS cases 
and separate them from well controls (Aslakson et al. 2006). 
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The PACE trial (White et al. 2011) found that both cognitive behaviour therapy (CBT) and graded 
exercise therapy (GET)  improved both fatigue and physical function  over 1 year when compared to 
standardised medical therapy alone. This study aimed to use the large database from the PACE trial 
baseline assessment to explore the heterogeneity of CFS, using not only self-reported measures of 
beliefs, behaviours, mood and co-morbidities, but also objective measures of activity, sleep and 
fitness.  
Methods 
Data collection 
Methods of participant recruitment and data collection for the trial have been described elsewhere 
(White et al. 2007; White et al. 2011). Briefly, 3158 new patients attending specialist chronic fatigue 
syndrome services at six centres in the UK were assessed for suitability. CFS was defined using the 
Oxford criteria (Sharpe et al. 1991), requiring disabling fatigue to be the primary complaint, with 
exclusion of alternative medical or psychiatric diagnoses. 640 patients were recruited and gave 
informed consent to participate.  Participants were subsequently randomly allocated to adaptive 
pacing therapy, cognitive behavioural therapy, or graded exercise therapy as supplements to 
specialist medical care, or to specialist medical care alone.  
Only baseline data was used for this study. It included a maximum dataset of 961 original or derived 
variables for each participant (see table A1 for data sources), though the actual number of data-
points for each patient was far fewer than this. The participant with the most data determined the 
number of variables within each category, hence, for example, medications were listed from 
Medication 1 to Medication 25, since at least one participant was taking 25 medications. As separate 
variables documented dosage, frequency, duration, etc, of treatment, there were a total of 225 
variables related to medication, most of which would not actually contain any data for any individual 
patient. Similar variable multiplication applied to healthcare utilisation, previous medical history and 
co-morbidities. In accordance with previous literature, variable reduction was initially undertaken 
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rationally, based upon previous research, clinical experience and logic (figure 1). For example, data 
on medication use was excluded in order to avoid defining subgroups by their treatment (Aslakson 
et al. 2006), as was healthcare utilisation data as this was felt to be influenced by many unrelated 
variables, such as availability of healthcare, geographical location, and previous personal experiences 
of healthcare. 
Despite the large number of variables attributed to previous medical history and co-morbidities, the 
majority of individual diagnoses, if present, were rare within the cohort. When present as co-morbid 
conditions, they were invariably also reported in past medical history, and the few more common 
co-morbidities displayed considerable overlap with other variables (e.g. mood or anxiety disorders 
covered in Standard Clinical Interview for DSM (SCID) diagnoses, fibromyalgia diagnoses overlapping 
with responses to questions on joint, muscle or back pain). The resulting multicollinearity within the 
dataset prevented principal component analysis (PCA), and infrequent diagnoses could contribute 
little to the overall variability of the dataset. All items from past medical history were therefore 
removed, as were co-morbidities that we thought were better represented elsewhere within the 
data. Infrequent or absent SCID diagnostic variables were removed due to the same rationale. Many 
other variables were then removed, since they constituted single items from scales where we 
considered that the summary scale scores or subscale summary scores would be more useful (e.g. 
Hospital Anxiety and Depression Scale, Cognitive Behavioural Response Questionnaire), or because 
we felt the variables were either unlikely to relate to subgroups of CFS, or represented outcomes of 
the condition, rather than causal factors (e.g. EQ-5D, further economic and demographic data). 
 
Substantial overlap also existed between many of the remaining questionnaires employed. The 
exclusion of overlapping variables is important in order to prevent such predictable correlations 
from producing artificial classes during latent class analysis (LCA). For example, CDC CFS criteria Q7 
Unrefreshing sleep vs. Jenkins Sleep Scale Q4 Wake up after your usual amount of sleep feeling tired 
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or worn out? Similarly, some data were represented in multiple variables, such as the derived 
daytime activity sub-groups and mean daytime activity. In both cases, correlation matrices were 
utilised to assist in the identification of such overlaps, and a decision was made on which variable to 
retain based upon which was believed to be the most clinically useful or significant. The removal of 
correlated pairs was again also necessary to reduce the multicollinearity of the dataset, a 
requirement for principal component analysis.  
Principal component analysis 
PCA was employed to assist our decisions on variable reduction, as in previous studies (Hickie et al. 
1995; Vollmer-Conna et al. 2006; Aslakson et al. 2009). Patients with missing data were excluded 
from the analysis, and non-binary variables for the remaining 541 patients were then dichotomised 
via median split to produce a binary categorical dataset. PCA was then performed, using SPSS 
version 22, on the orthogonally rotated correlation coefficient matrix of variables. PCA describes the 
total variability of a dataset whilst reducing it into a number of independent principal components. 
Each principal component was created by the weighted sum of multiple correlated individual 
variables. The first PCA described the maximum variability of the dataset. Each subsequent analysis 
did the same for the remainder of the variance, whilst remaining uncorrelated with all preceding 
principal components. Each component was typically defined by a few highly loaded variables, 
followed by many other variables with low loading values and hence minimal contribution. The 
utility of the technique is in identifying variables that achieve only very low loading across all 
identified principal components. Such variables were therefore removed from the dataset with 
minimal loss of the overall variance. By using PCA we were able to reduce substantially the number 
of variables needed in the subsequent latent class analysis. 
Latent class analysis 
In contrast to PCA, where the weighted variables are allocated to principal components, we used 
latent class analysis (LCA) (Latent Gold v5.0) to allocate each individual patient to a latent class. This 
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was achieved based upon their responses to the variables included in the analysis, which are 
described in detail in appendix A2. The assumption was that where there was an association 
between the responses of different patients to such observed variables, this was due to shared 
membership of an unobserved latent class. Class membership was then assigned to each patient in 
order to maximise the amount of variation of the dataset explained by class membership alone. The 
number of latent classes to be derived was specified prior to each analysis. In order to determine the 
optimum number of classes, the analysis was therefore repeated multiple times, each time 
requesting a higher number of classes. The derived models were then compared using statistical 
indices, together with an assessment of their perceived clinical utility. In keeping with previous work 
(Vollmer-Conna et al. 2006; Aslakson et al. 2009), we used the Akaike Information Criterion (with 3 
as penalising factor) (AIC3) to determine the optimum number of classes; lower AIC3 values 
indicated a better fit. 
Validation of latent classes 
In the absence of a gold standard for comparison, initial assessments of validity included 
comparisons to previous heterogeneity studies.  Additionally, we sought to demonstrate 
discriminative validity of the empirically derived subgroups by comparing them across pre-specified 
measures of functional and symptomatic severity, not included in either the PCA or LCA. These 
variables were chosen a priori, in keeping with the assessments of validity successfully utilised in 
previous studies (Aslakson et al. 2006; Aslakson et al. 2009). The Chalder fatigue questionnaire, 
Likert scoring (CFQ), the work and social adjustment scale (WSAS), and the 36 item short form health 
survey, physical function subscale (SF-36) were compared across subgroups using the Kruskal-Wallis 
test. (Ware & Sherbourne 1992; Mundt et al. 2002; Cella, Sharpe, et al. 2011) The SF-36 provides a 
measure of physical function, whilst the WSAS captures a more global measure of impairment or 
participation in life. In addition, we explored the relationship of our empirically derived subgroups 
with CDC and London criteria for CFS and ME, respectively, (The National Task Force on Chronic 
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Fatigue Syndrome 1994; Reeves et al. 2003) as well as age, sex and illness duration, using Chi-
squared tests.  
Results 
Following our initial review of the dataset, 100 variables were chosen for analysis; 51 were removed 
as they represented correlations and overlaps (figure 1), leaving 49 binary, categorical variables in 
the PCA.  Scree plots were used to determine the number of principal components to analyse based 
upon the point of inflection. PCA was used iteratively, repeatedly removing low-loading variables 
and re-running the analysis until a final dataset of 30 variables was achieved, each of which 
contributed substantially to the overall variance of the dataset (Table 1; see Table A2 for explanation 
of these variables). 
Initial LCA modelling revealed that 4 of the 30 variables (mean total sleep time, age, Borg Scale / % 
of maximum heart rate achieved [following step test], and body mass index) were contributing 
insignificantly to the analysis, and these were removed (figure 1). Models were therefore derived 
using 26 variables. The minimum AIC3 value was reached for the 6 class solution, but was only 
marginally higher for 5 classes (16,372 and 16,376, respectively). Both were therefore evaluated for 
perceived clinical utility.  
The 5 class solution is shown in table 2 and figure 2. The largest subgroup (“Core”, 33%) was 
determined by less severe scores across the majority of the variables, with an added association with 
good self-efficacy. This class had an absence of the features associated with functional somatic 
syndromes (FSS), which we define here as including the features of irritable bowel syndrome (IBS – 
stomach pain, constipation/diarrhoea, indigestion) or the features of fibromyalgia (FM – back pain, 
joint pain). There were also low scores for anxiety and depression. The quality of sleep was both 
subjectively and objectively good, with high daytime activity and low scores on the cognitive 
behavioural response questionnaire (CBRQ).  
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The second largest group (“Mood affected”, 21%), was defined by low to moderate scores on 
features of FSS, but very high scores on co-morbid major depressive disorder (MDD), co-morbid 
generalised anxiety disorder (GAD) and total HADS scores. CBRQ scores were moderate to high, 
particularly embarrassment and symptom focusing, and self-efficacy scores were moderate to low. 
Interestingly, the majority of patients in this class believed their symptoms to be the results of both 
physical and psychological factors (as opposed to purely or predominantly physical), and they had 
the highest levels of fitness. 
The third group (“FSS”, 21%), in contrast, had the highest scores across features of FSS, whilst MDD, 
GAD and HADS-total were low to moderate. Sleep was subjectively poor with low sleep efficiency, 
and CBRQ scores were moderately elevated. 
The fourth group (“Polysymptomatic”, 14%), had high scores on both features of FSS and mood. 
Physical symptoms of panic disorder, such as chest pain, palpitations and dyspnoea were also high, 
with a high proportion reporting new headache and dizziness. They had the highest responses to the 
CBRQ, very low self-efficacy, and largely believed their symptoms to be both physical and 
psychological in nature. Sleep was subjectively and objectively poor. 
The smallest group (“Avoidant-Inactive”, 11%), as for the core group, had low scores on features 
associated with FSS, anxiety and depression. In contrast, however, they had higher scores on the 
CBRQ, particularly for behaviour avoidance, fear avoidance and damage beliefs. In keeping with this, 
they were the most likely to believe their symptoms were physical in nature. Their sleep efficiency 
was low despite subjectively good quality sleep, and they had poor fitness and low daytime activity.  
The 6 class solution (data not shown) produced broadly similar groups. The mood group, however, 
was split into two. The larger division (18%) had low scores for symptoms of panic disorder, 
moderate CBRQ scores and high sleep efficiency. The smaller division (12%) had moderate features 
of panic disorder, high CBRQ scores, low sleep efficiency and higher daytime activity.  
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We concluded that the subgroups of the 5 class solution were most clinically useful, and hence this 
solution was taken forward for validation. 
Validation 
The initial inspection of the subgroups led to the consensus that they were consistent with the 
existing literature on CFS, particularly our “Core”, “Polysymptomatic” and “Mood” subgroups 
described previously. 
Comparison across the pre-specified measures of severity for the 5 class solution are shown in table 
3 and summarised in figure 3. The differences were highly significant across the subgroups on all 
validating variables, providing support for discriminative validity. The polysymptomatic and FSS 
groups had the most fatigue, and the polysymptomatic group also reported the most severe 
functional impairment on both the WSAS and SF-36. Such functional impairment was matched by 
the FSS group when assessed by SF-36, though this was less severe on the WSAS. The core and 
avoidant-inactive groups demonstrated the least fatigue and the least functional impairment, 
although this differed between the SF-36 and WSAS: the core group had the least severe WSAS 
score, and avoidant-inactive the least severe SF-36. 
Further validation was undertaken comparing the groups using age, sex, illness duration and 
whether they met the Centre for Disease Control (CDC) or London criteria for CFS (Reeves et al. 
2003; The National Task Force on Chronic Fatigue Syndrome 1994) (table 4). 
62% of patients met the CDC criteria for CFS, but differences across subgroups were not statistically 
significant (p = 0.12). In contrast, 53% of all patients met the London criteria for ME, and differences 
across subgroups could not be explained by chance alone (p < 0.001). This relationship, however, 
appeared to be driven by the low proportion of patients in the mood and polysymptomatic groups. 
This was to be expected, given that the high levels of co-morbid anxiety and depression that 
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characterised these subgroups would, by definition, result in exclusion from the London criteria 
(White et al. 2007). 
There was a significant difference between subgroups for sex (p = 0.014), with the FSS group, and to 
a lesser extent avoidant-inactive, having a relatively greater proportion of women. Age and illness 
duration did not differ across subgroups (data not shown). 
Discussion 
Summary of classes and validation 
This analysis provides further support for the heterogeneous nature of CFS in a large cohort of 
patients recruited from UK secondary care clinics. Five separate subgroups of CFS were defined 
based upon a combination of statistical likelihood and perceived clinical utility. The groups were 
predominantly defined by features of associated functional somatic syndromes, mood, self-efficacy 
ratings, cognitive behavioural responses questionnaire scores and assessments of sleep. These 
groups had face validity and were consistent with previous publications. As in previous studies 
(Aslakson et al. 2006; Aslakson et al. 2009), discriminative validity was demonstrated by showing 
significant differences across the classes in the independent, a priori measures of fatigue and 
disability. The polysymptomatic and FSS group had the greatest levels of fatigue and functional 
impairment, whilst both the mood and polysymptomatic groups tended to regard their symptoms as 
both physical and psychological in nature. 
Comment on validation 
Given the features used to define the polysymptomatic group, it is no surprise that they reported 
the greatest levels of fatigue and functional impairment. It is also logical that the functional somatic 
syndromes group, which suffered from the highest levels of back, joint and stomach pain, had a 
similarly high level of disability when assessed by the SF-36, which measures physical impairment. 
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In contrast, the avoidant-inactive group had the lowest impairment on the SF-36 physical function 
scale, but greater impairment on the WSAS. This may relate to the more global measure of 
impairment or participation in life captured by the WSAS. The avoidant-inactive group commonly 
reported features of behavioural avoidance, fear avoidance and concerns regarding the potential 
damaging effects of activity, which may therefore result in greater impairment of their ability to 
work, socialise and maintain relationships (represented by the WSAS), despite relatively preserved 
physical functioning (represented by the SF-36). 
Comparison to previous studies 
Despite the unique combination of variables used to define our groups, comparisons can be drawn 
with previously published studies of the heterogeneity of CFS. In particular, our polysymptomatic 
and FSS subgroups show similarities to those defined previously. Hickie et al found in multiple 
cohorts the presence of a polysymptomatic subgroup of CFS patients (Hickie et al. 1995; Wilson et al. 
2001). The authors concluded that this subgroup was related to ‘somatisation’ (a tendency to report 
multiple symptoms that were not related to established disease), and found in post-hoc 
comparisons that such patients had higher levels of psychiatric comorbidity. This is consistent with 
our results. In further work an additional pain predominant subgroup was identified in addition to 
the polysymptomatic and core groups (Hadzi-Pavlovic et al. 2000), which may be more resistant to 
conventional treatments such as CBT (Cella, Chalder, et al. 2011). Subgroups defined by many 
symptoms and pain-predominance were also key features of a recent, large study including 8,433 
CFS patients from UK and Dutch specialist centres (Collin et al. 2016).  
More recent work has focused on population derived samples with increasing use of biological 
parameters. As such samples included patients with CFS (Centers for Disease Control criteria), 
uncategorised chronic fatigue and unfatigued controls, as well as different variables, the extent of 
available comparison is limited. 
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Vollmer-Conna and colleagues defined five classes in an American population derived cohort, based 
upon the key features of obesity, sleep disturbance, metabolic strain, multiplicity of symptoms and 
depressed mood(Vollmer-Conna et al. 2006). In contrast to this, we did not find that BMI 
contributed to the subgroup model. It should be noted, however, that BMI of our cohort was 
substantially lower than that of Vollmer-Conna’s study (median BMI 24.7 vs. 29, respectively), that 
BMI may varying significantly between nations, and that the authors of the American study 
concluded that this raised BMI is likely to be contributing to the fatigue and relative sleep hypnoea 
identified in their sample.  Despite such differences, however, Vollmer-Conna’s description of two 
highly symptomatic and depressed groups, which was replicated in a separate American cohort 
(Aslakson et al. 2009), is reminiscent of the subgroups previously described and demonstrated again 
in this study. 
There is support for the role of sleep in defining CFS subgroups, as identified by Vollmer-Conna et al 
and again found in this study. In a sample of 343 CFS patients, polysomnography identified 30% had 
a primary sleep disorder that could explain their fatigue, and the remaining patients could be 
grouped in 4 polysomnography subtypes (Gotts et al. 2013). As we have found, sleep efficiency 
varied between these subgroups, together with aspects of total sleep and sleep stage duration.  
 
Our finding of a separate mood disorder group is in keeping with the well-recognised role that mood 
disorders play in CFS (Wessely et al. 1996; Harvey et al. 2009). Previous studies using latent class 
analysis have found that depression was an important contributing factor in their models (Aslakson 
et al. 2006; Aslakson et al. 2009). Similarly, it has been recognised that CFS, fibromyalgia and IBS, 
which have been collectively referred to as functional somatic syndromes , often cluster together 
(Aaron & Buchwald 2001; Mcbeth et al. 2015). It has been suggested that this may be due to shared 
predisposing factors, perhaps relating to mechanisms of chronic central nervous system sensitisation 
(Kato et al. 2009; Bourke et al. 2015) or comorbid mood disorders (Mcbeth et al. 2015), which, 
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together with anxiety disorders, are common in patients with  functional somatic syndromes 
(Janssens et al  2015). Taken together, the delineation of a group characterised by predominant 
functional somatic syndrome features, a group with predominant mood features, and a 
polysymptomatic group with features of both is attractive in its simplicity, and could have clinical 
utility.  
Critique 
Strengths 
The size and quality of the PACE trial database provides a number of strengths. The 640 patients 
were carefully screened to ensure accuracy of diagnosis, allowing 541 patients with complete 
datasets to be analysed. This large sample from six CFS clinics is representative of the CFS population 
attending secondary care facilities around the UK. The range of baseline variables incorporated into 
the analysis provided detailed characterisation of this group, including measures of fitness, daytime 
activity, sleep quality, and illness beliefs and coping which have not previously been included in CFS 
heterogeneity studies. 
Limitations 
As with all trial samples, it is possible that systematic differences existed between the trial sample 
and the UK CFS population, limiting the external validity of our results. The use of the broad and 
widely used Oxford criteria (Sharpe et al. 1991) and the inclusion of Action for ME representatives 
on the trial management committee (with the resulting addition of the adaptive pacing therapy arm) 
may have aided recruitment of a representative patient cohort. The participants, were still selected 
from secondary care facilities, had to be able to attend research and treatment sessions (and so 
were generally ambulant), and may be inherently more motivated to partake in treatment therapies 
than non-trial participants. The extent to which the results may be generalised to primary care 
patients, the severely disabled and patients with poor motivation to engage in therapies may 
therefore be limited. 
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Whilst we describe our subgroups as empirically derived, we acknowledge that the subgroups 
identified will be limited by the variables selected for inclusion, and that the majority of the 
decisions relating to variable reduction were undertaken post hoc. A large number of redundant 
variables, such as 25 separate variables for different medications, were removed as they rarely 
contained patient data (most patients were taking far less than 25 medicines). Reference to 
published literature and clinical experience, shaped further decisions to omit variables, aimed at 
maximising retention of what we perceived to be clinically useful data whilst removing the 
substantial overlap between many other variables. Whilst such decisions are liable to a selection 
bias, the use of PCA as a variable reduction tool once an initial list of plausible variables was 
compiled should have minimised this.  
Similarly a post hoc decision was made when choosing the number of classes to include in the final 
latent class model. By using a combination of statistical indices and clinical experience, as in previous 
literature, however, we have been able to derive clinically recognisable and subsequently validated 
subgroups of chronic fatigue syndrome. Whereas a six class solution was minimally more statistically 
plausible, we feel the added complexity would have detracted from its future clinical utility.  
We did not include haematological or biochemical data and were unable to investigate the 
endocrine, metabolic and immunological abnormalities that have previously been reported. We may 
also have inadvertently excluded other measures that may have revealed different sub-groups. Our 
assessments of sleep using actigraphy may also not be as detailed as the polysomnography that have 
been used in previous studies (Vollmer-Conna et al. 2006; Gotts et al. 2013). The validity of 
actigraphy in assessing sleep has, however, been shown to be acceptable (Tryon 2004). It is also 
clinically more practical, and has the advantage of being able to capture daytime activity. Clinicians 
might use alternative measures of activity, such as pedometers or Fitbit in clinical practice.  
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Conclusion 
In conclusion, we have used a large, high quality dataset of variables from participants in the PACE 
trial to empirically identify and validate five subgroups of chronic fatigue syndrome. These provide 
evidence for the clinical heterogeneity of CFS. We have replicated previous findings of subgroups 
defined by mood disorders, functional somatic syndromes, and having many symptoms. A novel 
finding is the avoidant-inactive subgroup. Future work should focus on the aetiology and 
pathophysiologies of these subgroups, as well as their specific treatment responses. For example, 
one could hypothesise that the mood disorder subgroup may preferentially benefit from 
interventions targeted at depression and anxiety, especially given the known increased risk of 
suicide in patients with CFS (Roberts et al. 2016). Similarly, the avoidant-inactive group may 
particularly benefit from CBT addressing their negative cognitions related to the damaging effects of 
exercise and subsequent activity avoidance. 
Future studies of aetiology and response to treatment could use these subgroups in order to obtain 
more homogeneous groups. The identification of these subgroups in clinical practice may allow 
translation of such research into potentially improved treatments. 
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 Figure Legends 
 
Figure 1 – Summary of variable reduction 
 
Footnote: Variable reduction was initially undertaken in accordance to clinical knowledge and previous literature. Correlation 
matrices were then used to remove overlap. Principal component analysis then identified variables minimally contributing to the 
overall variance, and four further variables were removed during latent component analysis due to a lack of statistical 
contribution to the derived models. PMHx = Past Medical History; SCID = Standardised Clinical Interview for DSM IV; HADS = 
Hospital Anxiety and Depression Scale; CBRQ = Cognitive Behavioural Responses Questionnaire; EQ5D = EuroQoL 5 items; 
PCA = Principal Components Analysis; LCA = Latent Class Analysis. 
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Figure 2 – Subgroups – 5 class solution 
 
 
 
Footnote: Diagrammatic representation of the 5 class solution, highlighting the key features used to identify each subgroup. 
FSS, functional somatic syndromes; CBRQ, cognitive and behavioural response questionnaire.  
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 Figure 3 – Subgroups – Validation of the 5 class solution 
 
 
Footnote: Diagrammatic representation of the statistically significant comparisons used to provide support for discriminative 
validity. 
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